Get started
CATALYST PHARMACEUCATALYST PHARMACEUCATALYST PHARMACEU

CATALYST PHARMACEU

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Seasonals

CN2 chart


Full chart

CN2 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.23 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
14.378
Basic EPS (TTM)
1.051 CHF
Net income (FY)
‪60.12 M‬ CHF
Revenue (FY)
‪335.26 M‬ CHF
Shares float
‪105.83 M‬
Beta (1Y)
1.24

Employees


Employees (FY)
167
Change (1Y)
+85 +103.66%
Revenue / Employee (1Y)
‪2.38 M‬ CHF
Net income / Employee (1Y)
‪427.60 K‬ CHF

About Catalyst Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Richard John Daly
Headquarters
Coral Gables
Website
catalystpharma.com
Founded
2002
FIGI
BBG00LVDFHG9
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CN2 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CN2 is 20.217 CHF — it has increased by 35.37% in the past 24 hours. Watch CATALYST PHARMACEU stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange CATALYST PHARMACEU stocks are traded under the ticker CN2.
CN2 stock has risen by 35.37% compared to the previous week, the month change is a 35.37% rise, over the last year CATALYST PHARMACEU has showed a 38.57% increase.
We've gathered analysts' opinions on CATALYST PHARMACEU future price: according to them, CN2 price has a max estimate of 33.76 CHF and a min estimate of 24.88 CHF. Watch CN2 chart and read a more detailed CATALYST PHARMACEU stock forecast: see what analysts think of CATALYST PHARMACEU and suggest that you do with its stocks.
CN2 reached its all-time high on Nov 13, 2024 with the price of 20.217 CHF, and its all-time low was 14.590 CHF and was reached on Jan 27, 2023. View more price dynamics on CN2 chart.
See other stocks reaching their highest and lowest prices.
CN2 stock is 26.13% volatile and has beta coefficient of 1.24. Track CATALYST PHARMACEU stock price on the chart and check out the list of the most volatile stocks — is CATALYST PHARMACEU there?
Today CATALYST PHARMACEU has the market capitalization of ‪2.23 B‬, it has increased by 2.03% over the last week.
Yes, you can track CATALYST PHARMACEU financials in yearly and quarterly reports right on TradingView.
CATALYST PHARMACEU is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
CN2 earnings for the last quarter are 0.30 CHF per share, whereas the estimation was 0.26 CHF resulting in a 15.13% surprise. The estimated earnings for the next quarter are 0.30 CHF per share. See more details about CATALYST PHARMACEU earnings.
CATALYST PHARMACEU revenue for the last quarter amounts to ‪107.14 M‬ CHF, despite the estimated figure of ‪104.58 M‬ CHF. In the next quarter, revenue is expected to reach ‪118.60 M‬ CHF.
CN2 net income for the last quarter is ‪37.19 M‬ CHF, while the quarter before that showed ‪36.68 M‬ CHF of net income which accounts for 1.40% change. Track more CATALYST PHARMACEU financial stats to get the full picture.
No, CN2 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 167.00 employees. See our rating of the largest employees — is CATALYST PHARMACEU on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CATALYST PHARMACEU EBITDA is ‪179.35 M‬ CHF, and current EBITDA margin is 30.12%. See more stats in CATALYST PHARMACEU financial statements.
Like other stocks, CN2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CATALYST PHARMACEU stock right from TradingView charts — choose your broker and connect to your account.